BCG - medac România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

bcg - medac

medac gesellscaft fur klinische spezialprÄparate - germania - vaccin bcg - pulb.+solv. pt. susp. intravezicala - cytokine si imunomodulatoare alte cytokine si imunomodulatoare

BCG Vaccine pulbere si solvent pentru suspensie injectabila 1 ml (0,05 ml - 20 doze/0,1 ml - 10 doze) Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

bcg vaccine pulbere si solvent pentru suspensie injectabila 1 ml (0,05 ml - 20 doze/0,1 ml - 10 doze)

serum institute of india pvt.ltd - vaccin bcg viu, atenuat - pulbere si solvent pentru suspensie injectabila - 1 ml (0,05 ml - 20 doze/0,1 ml - 10 doze)

BCG Vaccine (Freeze Dried) - pulbere şi solvent pentru suspensie injectabilă Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

bcg vaccine (freeze dried) - pulbere şi solvent pentru suspensie injectabilă

serum institute of india pvt.ltd - vaccin bcg viu, atenuat - pulbere şi solvent pentru suspensie injectabilă - -

BCG  VACCINE România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

bcg vaccine

bul bio-ncipd ltd. - bulgaria - vaccin bcg - pulb+solv.pt.susp.inj. - 0,05mg/doza - vaccinuri bacteriene vaccinuri tuberculoase

BCG 10 ANTI-TUBERCULOSIS VACCINE România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

bcg 10 anti-tuberculosis vaccine

biomed-lublin - polonia - vaccin bcg - pulb.+solv. pt. susp. inj. - 0,05mg/doza - vaccinuri bacteriene vaccinuri tuberculoase

ONKO BCG 100 România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

onko bcg 100

biomed-lublin - polonia - vaccin bcg - pulb.+solv. pt. susp. intravezicala - cytokine si imunomodulatoare alte cytokine si imunomodulatoare

ONKO BCG 100 România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

onko bcg 100

synthaverse s.a. - polonia - vaccin bcg - pulb+solv.pt.susp. intravezicala - 100mg/ml - cytokine si imunomodulatoare alte cytokine si imunomodulatoare

Jayempi Uniunea Europeană - română - EMA (European Medicines Agency)

jayempi

nova laboratories ireland limited - azathioprine - respingerea grefei - imunosupresoare - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.